文献速递细菌感染、耐药与抗菌药物

抗生素精准给药软件在危重感染成人中的预测性能

Predictive performance of an antibiotic precision dosing software program in critically ill adults with infection.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究基于GUIDE试验数据,评估ID-ODSTM软件对危重成人抗菌药物浓度的先验与后验预测性能。结果显示万古霉素先验预测达标,β-内酰胺类先验预测不达标;后验预测仅头孢吡肟全面达标。约三分之一先验预测导致不必要的剂量调整。

要点

  • 万古霉素先验预测性能可接受,β-内酰胺类先验预测不达标。
  • β-内酰胺类后验预测准确性改善,但仅头孢吡肟精度与F20/F30达标。
  • 约三分之一先验预测导致不必要的剂量调整。

核心结论

  • 在异质性成人ICU人群中,万古霉素先验预测性能可接受,而β-内酰胺类先验预测性能不可接受。
  • β-内酰胺类后验预测性能改善,但仅头孢吡肟满足全部验收标准。

研究设计与样本

  • 基于既往GUIDE试验中危重成人感染患者的临床与人口学数据,使用ID-ODSTM软件进行先验和后验浓度预测。
  • β-内酰胺类分析纳入81例患者,万古霉素分析纳入25例患者。

主要发现

  • β-内酰胺类先验预测未达到任何预设验收标准(合并MDPE -35%,MDAPE 58%)。
  • β-内酰胺类后验预测合并MDPE -3.6%,满足准确性验收标准,但仅头孢吡肟满足精度及F20和F30验收。
  • 万古霉素先验预测满足所有准确性和精度验收标准。
  • 约三分之一先验预测导致不必要的剂量调整;后验预测一致性相似,但美罗培南预测中20%出现过度预测。

关键数值与推荐

  • 预设验收标准:MDPE ≤20% 和 MDAPE ≤30%,以及F20和F30指标。
  • β-内酰胺类先验合并MDPE -35%、MDAPE 58%;后验合并MDPE -3.6%。
  • 万古霉素先验预测满足所有验收标准。

临床怎么用

  • 万古霉素可考虑使用该软件进行先验预测指导给药。
  • β-内酰胺类不宜仅依赖先验预测,后验预测可能改善准确性但仅头孢吡肟全面达标。
  • 需警惕先验预测导致的不必要剂量调整及美罗培南后验过度预测。

局限性

  • 研究基于既往GUIDE试验数据,样本量有限(β-内酰胺类81例,万古霉素25例)。
  • 仅评估了五种药物,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Critically ill patients exhibit altered pharmacokinetics, rendering antibiotic dosing challenging. Achieving therapeutic antibiotic exposures may be improved with the use of precision dosing software programs. OBJECTIVES: To quantify and compare both a priori and a posteriori predictive performance of an antibiotic precision dosing software program in a heterogenous cohort of critically ill adults with infection. METHODS: The precision dosing program, ID-ODSTM, was used to predict a priori and a posteriori concentrations for piperacillin, meropenem, cefepime, flucloxacillin and vancomycin using clinical and demographic data derived from a previous study in critically ill adults (GUIDE trial). Predicted concentrations were compared to observed concentrations using pre-specified acceptance criteria (median predictive error (MDPE) ≤20% and median absolute predictive error (MDAPE) ≤30%), along with F20 and F30 metrics. Furthermore, the impact of predictions on theoretical dosing recommendations to achieve pre-defined drug exposures was assessed. RESULTS: The a priori predictive performance in 81 patients administered beta-lactams did not meet any pre-specified acceptance criteria (pooled MDPE -35% and MDAPE 58%). However, all beta-lactams met accuracy acceptance criteria for the a posteriori approach (pooled MDPE -3.6%), although only cefepime demonstrated acceptable precision and F20 and F30 acceptance. In 25 patients administered vancomycin, a priori predictive performance met all acceptance criteria for accuracy and precision.When assessing a priori theoretical dosing recommendation concordance, approximately one in three predictions led to an unnecessary dosing action. Concordance was similar with an a posteriori approach, however, overprediction was observed in 20% of meropenem predictions. CONCLUSIONS: In a heterogenous adult ICU population, the a priori predictive performance of vancomycin was shown to be acceptable. Conversely, the a priori predictive performance for the beta-lactams was not acceptable. Although predictive performance improved with the a posteriori approach for beta-lactams, only cefepime met acceptance criteria.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Williams P, Cotta MO, Wilks K, et al. Predictive performance of an antibiotic precision dosing software program in critically ill adults with infection. J Antimicrob Chemother. 2026. PMID: 42497383. doi:10.1093/jac/dkag234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。